Gilead Sciences, Inc. (BMV:GILD)
Mexico · Delayed Price · Currency is MXN | Market Cap | 2.81T +11.8% |
| Revenue (ttm) | 536.07B +3.5% |
| Net Income | 166.14B +54.5% |
| EPS | 132.55 +55.4% |
| Shares Out | n/a |
| PE Ratio | 16.94 |
| Forward PE | n/a |
| Dividend | 57.59 (2.61%) |
| Ex-Dividend Date | Jun 15, 2026 |
| Volume | 8 |
| Open | 2,208.00 |
| Previous Close | 2,400.00 |
| Day's Range | 2,208.00 - 2,208.00 |
| 52-Week Range | 2,025.32 - 2,618.71 |
| Beta | 0.34 |
| Analysts | n/a |
| Price Target | n/a |
| Earnings Date | Aug 4, 2026 |
About Gilead Sciences
Gilead Sciences, Inc., a biopharmaceutical company, discovers, develops, and commercializes medicines in the areas of unmet medical need in the United States, Europe, and internationally. The company provides Biktarvy, Descovy, Genvoya, Odefsey, Sunlenca, Symtuza, and YeztugoFor the treatment of HIV-1 infection in patients. It also provides Epclusa, Livdelzi, and Vemlidy to treat chronic hepatitis C virus, primary biliary cholangitis, and chronic hepatitis B virus; Tecartus, a T-cell therapy for the treatment of adult patients; Trodelvy, an inj... [Read more]
Financial Performance
In 2025, Gilead Sciences's revenue was $29.44 billion, an increase of 2.40% compared to the previous year's $28.75 billion. Earnings were $8.51 billion, an increase of 1672.92%.
Financial numbers in USD Financial StatementsNews
Gilead Sciences to Release Second Quarter 2026 Financial Results on Tuesday, August 4, 2026
FOSTER CITY, Calif.--(BUSINESS WIRE)-- #Earnings--Gilead Sciences, Inc. (Nasdaq: GILD) announced today that its second quarter 2026 financial results and guidance will be released on Tuesday, August 4...
Gilead, Merck weekly HIV pill keeps virus suppressed in late-stage trials
Gilead Sciences and Merck said on Tuesday their experimental once-weekly HIV pill kept the virus suppressed in two late-stage trials, supporting regulatory filings for what could become the first re...
Gilead to present new HIV research at AIDS 2026
Gilead (GILD) Sciences announced its upcoming participation in the 26th International AIDS Conference taking place in Rio de Janeiro, Brazil, from July 26-31. Featured as part of the AIDS 2026…
Gilead, Merck report ‘high’ rates of virologic suppression in ISLEND trials
Gilead Sciences (GILD) and Merck (MRK) announced that the detailed outcomes from the Phase 3 ISLEND-1 and ISLEND-2 trials will be presented for the first time at the 26th International…
Gilead to Present New HIV Research at AIDS 2026 Across Prevention, Treatment and Cure
FOSTER CITY, Calif.--(BUSINESS WIRE)--Gilead Sciences, Inc. (Nasdaq: GILD) today announced its upcoming participation in the 26th International AIDS Conference (AIDS 2026) taking place in Rio de Janei...
Investigational Once-Weekly Oral HIV Treatment Regimen of Islatravir and Lenacapavir Maintained Virological Suppression in Adults With HIV Who Switched Antiretroviral Therapy
FOSTER CITY, Calif. & RAHWAY, N.J.--(BUSINESS WIRE)--Gilead Sciences, Inc. (Nasdaq: GILD) and Merck (NYSE: MRK), known as MSD outside of the United States and Canada, today announced that the detailed...
Gilead downgraded at Leerink on long-term headwinds to HIV PrEP expansion
As previously reported, Leerink downgraded Gilead (GILD) to Market Perform from Outperform with a price target of $127, down from $146. The firm, which is anticipating long-term headwinds to HIV…
Gilead downgraded to Market Perform from Outperform at Leerink
Leerink analyst Daina Graybosch downgraded Gilead (GILD) to Market Perform from Outperform with a price target of $127, down from $146.
Congo begins trial of Gilead's experimental antiviral for Ebola Bundibugyo
Researchers in the Democratic Republic of Congo said on Tuesday they have started enrolling participants in a trial testing Gilead Sciences' experimental antiviral obeldesivir as a post-exposure trea...
Gilead price target lowered to $166 from $168 at Morgan Stanley
Morgan Stanley lowered the firm’s price target on Gilead (GILD) to $166 from $168 and keeps an Overweight rating on the shares. Biotech could benefit from broader market leadership and…
Gilead price target lowered to $156 from $157 at Truist
Truist lowered the firm’s price target on Gilead (GILD) to $156 from $157 and keeps a Buy rating on the shares as part of a broader research note previewing Q2…
Gilead price target lowered to $120 from $122 at RBC Capital
RBC Capital analyst Brian Abrahams lowered the firm’s price target on Gilead (GILD) to $120 from $122 and keeps a Sector Perform rating on the shares as part of a…
Gilead upgraded to Buy from Hold at HSBC
HSBC analyst Morten Herholdt upgraded Gilead (GILD) to Buy from Hold with a price target of $155, up from $133. The market is too pessimistic on the HIV market post-dolutegravir…
Merck says FDA approves Keytruda and Keytruda Qlex in combo with Trodelvy
Merck (MRK) announced the U.S. FDA approved Keytruda and Keytruda Qlex, each in combination with Trodelvy, Gilead’s (GILD) Trop-2-directed antibody-drug conjugate, for the first-line treatment of adul...
U.S. FDA Approves Trodelvy® for First-Line Treatment of Metastatic Triple-Negative Breast Cancer
FOSTER CITY, Calif.--(BUSINESS WIRE)--Gilead Sciences, Inc. (Nasdaq: GILD) today announced that the U.S. Food and Drug Administration (FDA) has approved Trodelvy® (sacituzumab govitecan-hziy), a first...
For decades, the only first treatment for one of the deadliest breast cancers was standard chemotherapy. Now there are two newly approved drugs.
AstraZeneca and Gilead have won approval for treatments of an advanced form of the disease.
FDA approves Gilead’s Trodelvy for two indications
The Food and Drug Administration approved sacituzumab govitecan-hziy, or Trodelvy from Gilead Sciences (GILD), for two indications in adults with triple-negative breast cancer, the regulator announced...
Gilead announces EC grants marketing authorization for Trodelvy
Gilead (GILD) Sciences announced that the European Commission has granted marketing authorization for Trodelvy as monotherapy for the treatment of adult patients with unresectable or metastatic triple...
European Commission Approves Trodelvy® as a First-Line Treatment for Metastatic Triple-Negative Breast Cancer Patients Not Candidates for PD-(l)1 Inhibitors
FOSTER CITY, Calif.--(BUSINESS WIRE)--Gilead Sciences, Inc. (Nasdaq: GILD) today announced that the European Commission (EC) has granted marketing authorization for Trodelvy® (sacituzumab govitecan-hz...
Gilead announces FDA approval of sNDA for Yeztugo
Gilead (GILD) Sciences announced the U.S. FDA accepted its supplemental New Drug Application for Yeztugo 300-mg tablet as a potential once-weekly oral formulation for the prevention of HIV as pre-expo...
U.S. FDA Accepts Gilead's Application for Investigational Once-Weekly Oral Yeztugo, Potentially the First Long-Acting Pill for HIV Prevention
FOSTER CITY, Calif.--(BUSINESS WIRE)--Gilead Sciences, Inc. (Nasdaq: GILD) today announced the U.S. Food and Drug Administration (FDA) accepted its supplemental New Drug Application (sNDA) for Yeztugo...
Gilead Mobilizes Rapid Donation of Remdesivir to Support Ebola Response, Building on Decade-Long Commitment to Outbreak Relief
FOSTER CITY, Calif.--(BUSINESS WIRE)-- #Ebola--Gilead Sciences today announced a donation of more than 2,000 vials of its intravenous antiviral therapy, remdesivir, to the Republic of Uganda to suppor...
National AIDS Memorial and the Gilead Foundation Launch Major Investment to Expand HIV/AIDS Education and Community Leadership
SAN FRANCISCO & FOSTER CITY, Calif.--(BUSINESS WIRE)--The National AIDS Memorial together with the Gilead Foundation today announced a transformative three-year, ~$3 million commitment to help preserv...
Healthcare ETFs: From Broad Exposure to Big Breakthroughs
With AI and space dominating many of the market's most popular investment themes, it can be difficult to find differentiated opportunities. Healthcare is often viewed as one of the more defensive sect...